Pulmonary fibrosis and Enzymes.
Many of those suffering from pulmonary fibrosis have switched over to enzymatic therapy due to the dangers that are associated with traditional corticosteroids. When it comes to enzymatic therapy, certain proteolytic enzymes have been shown to be extremely beneficial when it comes to fibrin in the lungs. Proteolytic enzymes, such as Nattokinase and Serrapeptase, have been shown to be effective against the symptoms associated with pulmonary fibrosis.
Pulmonary fibrosis, Serrapeptase and Nattokinase.
Systemic enzyme therapy is used by those with pulmonary fibrosis to help break down pulmonary scar tissue, prevent further fibrin accumulation in the lungs and improve overall circulation by dissolving fibrin clots in the bloodstream. By enhancing circulation throughout the body, systemic enzymes maximize oxygen delivery to all tissues.
Serrapeptase, an anti-inflammatory and fibrinolytic enzyme, can help with chronic inflammatory diseases which lead to conditions such as pulmonary fibrosis. By acting on areas of localized inflammation, serrapeptase may target the breakdown of fibrin and reduction of inflammation by lowering CRP levels.
Nattokinase's ability to dissolve fibrin buildup in the body renders it to be a very potent fibrinolytic enzyme that can help reduce fibrin accumulation. The role of nattokinase on plasmin activator inhibitor-1 in fibrosis has been well-documented in several animal models. Overexpression of PA-1 has been hypothesized as promoting ECM deposition by decreasing PA activity and inhibiting degradation of the ECM. Aside from decreasing fibrinolytic activity, overexpression of PA-1 also contributes to the development of fibrosis. Nattokinase is able to directly digest fibrin while inactivating the pro-fibrin effects of PA-1, and is considered both a treatment for existing fibrosis and a preventative approach to fibrosis progression.
Proteases have been shown to be efficient in eliminating fibrin from the lungs. In an in vivo study, rats with induced intravascular coagulation and inhibited fibrinolysis were treated with oral proteolytic enzymes, which break down fibrin and scar tissue in the lungs. Researchers report that proteases have direct effects in degradation of fibrin. The efficacy of proteases in reducing inflammation and cardiac manifestations can be shown by measuring CRP and ESR levels in blood tests before and after enzyme supplementation, both of which predict long-term cardiovascular disease.
Enzymes have enabled many to skip the countless of pharmaceutical drugs that exist in the current market when it comes to conditions involving inflammation like pulmonary fibrosis. In comparison, nonsteroidal anti-inflammatory drugs have been shown to cause harmful side-effects which can bring about many future complications.
Pulmonary fibrosis, Serrapeptase and Nattokinase.
Systemic enzyme therapy is used by those with pulmonary fibrosis to help break down pulmonary scar tissue, prevent further fibrin accumulation in the lungs and improve overall circulation by dissolving fibrin clots in the bloodstream. By enhancing circulation throughout the body, systemic enzymes maximize oxygen delivery to all tissues.
Serrapeptase, an anti-inflammatory and fibrinolytic enzyme, can help with chronic inflammatory diseases which lead to conditions such as pulmonary fibrosis. By acting on areas of localized inflammation, serrapeptase may target the breakdown of fibrin and reduction of inflammation by lowering CRP levels.
Nattokinase's ability to dissolve fibrin buildup in the body renders it to be a very potent fibrinolytic enzyme that can help reduce fibrin accumulation. The role of nattokinase on plasmin activator inhibitor-1 in fibrosis has been well-documented in several animal models. Overexpression of PA-1 has been hypothesized as promoting ECM deposition by decreasing PA activity and inhibiting degradation of the ECM. Aside from decreasing fibrinolytic activity, overexpression of PA-1 also contributes to the development of fibrosis. Nattokinase is able to directly digest fibrin while inactivating the pro-fibrin effects of PA-1, and is considered both a treatment for existing fibrosis and a preventative approach to fibrosis progression.
Proteases have been shown to be efficient in eliminating fibrin from the lungs. In an in vivo study, rats with induced intravascular coagulation and inhibited fibrinolysis were treated with oral proteolytic enzymes, which break down fibrin and scar tissue in the lungs. Researchers report that proteases have direct effects in degradation of fibrin. The efficacy of proteases in reducing inflammation and cardiac manifestations can be shown by measuring CRP and ESR levels in blood tests before and after enzyme supplementation, both of which predict long-term cardiovascular disease.
Enzymes have enabled many to skip the countless of pharmaceutical drugs that exist in the current market when it comes to conditions involving inflammation like pulmonary fibrosis. In comparison, nonsteroidal anti-inflammatory drugs have been shown to cause harmful side-effects which can bring about many future complications.